Please login to the form below

Private Public Partnership (PPP) in Health Care

The health care and life sciences sectors’ shared mission of improving the quality and longevity of patients’ lives has kept them consistently at the forefront of innovation. Despite this common purpose and drive, it has been difficult for public health care organizations to partner with private life sciences companies in sustained and meaningful ways. Historically, public–private partnerships (PPPs) have focused on the creation of health care infrastructure, including the establishment of hospital buildings and care delivery models. In Europe, we have seen some examples of small–scale PPPs and PPP–hybrid models focused purely on service provision, altering the way in which the participating public organizations receive and pay for health care services. What exactly is a PPP in health care? Is a PPP suitable for our clients?

26th February 2016



Company Details

EY Life Sciences

Contact Website

Ernst & Young LLP
1 More London Place
United Kingdom

Latest content on this profile

Leveraging HCP Transparency Insights to Drive Future Customer Investments
EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness
EY Life Sciences
EY Life Sciences Sector Update
Asia-Pacific and Japan
EY Life Sciences
A roadmap to strategic drug pricing
The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. Pharma firms must identify products that will benefit from innovative pricing models, and then forge the types of collaborations that will support those models.
EY Life Sciences
The growing necessity for pharma to become a true health delivery partner of the NHS

EY Life Sciences
What does patient-centricity, outcomes-driven R&D mean to you?
The shift to a patient-centric, outcomes-based business model in Life Sciences has a fundamental impact on R&D. EY can help you adapt your R&D model today so you remain relevant in the future.
EY Life Sciences
Better Insights Come from Better Evidence
Over the last few years, health has moved towards an outcome-driven and patient-centric ecosystem. This era is driving patients, payers and healthcare providers to become super-consumers, with pharmaceutical companies needing to create real information evidence from all the data that they have at their disposal. However, with the exponential proliferation of digital data and the increasingly fragmented nature of enterprise systems; organisations everywhere are suffering from data chaos.
EY Life Sciences